Celyad Oncology Announces Appointment of Matt Kane as Chief Executive Officer
Celyad Oncology (Euronext: CYAD) has appointed Matt Kane as its new Chief Executive Officer, effective October 1st, 2024. Kane brings over 20 years of experience in entrepreneurial, CEO, and board roles, with expertise in genome editing and allogeneic CAR T-cell therapies. His career highlights include:
- Raising over $500M in equity financings
- Forming partnerships valued at over $4B
- Co-founding Precision BioSciences (DTIL) in 2006
- Leading Precision's IPO and development of four allogeneic CAR T therapies
- Recent CEO role at Tune Therapeutics, an epigenetic editing company
Kane's appointment aligns with Celyad's focus on CAR T technology and ambitious plans for growth and development in the oncology space.
Celyad Oncology (Euronext: CYAD) ha nominato Matt Kane come nuovo Amministratore Delegato, con effetto dal 1 ottobre 2024. Kane porta con sé oltre 20 anni di esperienza in ruoli imprenditoriali, di CEO e di consiglio, con competenze in editing genico e terapie CAR T-cell allogeniche. I momenti salienti della sua carriera includono:
- Raccolta di oltre 500 milioni di dollari in finanziamenti azionari
- Creazione di partnership del valore superiore a 4 miliardi di dollari
- Co-fondazione di Precision BioSciences (DTIL) nel 2006
- Guidare l'IPO di Precision e lo sviluppo di quattro terapie CAR T allogeniche
- Ruolo recente come CEO di Tune Therapeutics, un'azienda di editing epigenetico
La nomina di Kane si allinea con l'attenzione di Celyad sulla tecnologia CAR T e con i suoi ambiziosi piani di crescita e sviluppo nel settore dell'oncologia.
Celyad Oncology (Euronext: CYAD) ha nombrado a Matt Kane como su nuevo Director Ejecutivo, con efecto a partir del 1 de octubre de 2024. Kane aporta más de 20 años de experiencia en roles empresariales, como CEO y en juntas directivas, con experiencia en edición del genoma y terapias CAR T-célula alogénicas. Los aspectos más destacados de su carrera incluyen:
- Recaudación de más de 500 millones de dólares en financiamiento de capital
- Formación de asociaciones valoradas en más de 4 mil millones de dólares
- Cofundación de Precision BioSciences (DTIL) en 2006
- Liderar la OPI de Precision y el desarrollo de cuatro terapias CAR T alogénicas
- Rol reciente como CEO de Tune Therapeutics, una empresa de edición epigenética
La designación de Kane se alinea con el enfoque de Celyad en la tecnología CAR T y sus ambiciosos planes de crecimiento y desarrollo en el espacio oncológico.
Celyad Oncology (Euronext: CYAD)은 Matt Kane을 2024년 10월 1일부터 새로운 CEO로 임명했습니다. Kane은 기업가, CEO 및 이사회 역할에서 20년 이상의 경험을 가지고 있으며, 유전체 편집 및 알로겐 CAR T 세포 요법에 대한 전문성을 보유하고 있습니다. 그의 경력 하이라이트는 다음과 같습니다:
- 5억 달러 이상의 자본 조달
- 40억 달러 이상의 가치가 있는 파트너십 체결
- 2006년에 Precision BioSciences (DTIL) 공동 창립
- Precision의 IPO와 4개의 알로겐 CAR T 요법 개발 주도
- 최근 epigenetic editing 회사인 Tune Therapeutics의 CEO 역할
Kane의 임명은 Celyad의 CAR T 기술에 대한 초점과 온콜로지 분야에서의 성장 및 개발을 위한 야심찬 계획과 일치합니다.
Celyad Oncology (Euronext: CYAD) a nommé Matt Kane en tant que nouveau Directeur Général, à compter du 1er octobre 2024. Kane apporte plus de 20 ans d'expérience dans des rôles d'entrepreneur, de PDG et au sein de conseils d'administration, avec une expertise en édition du génome et en thérapies CAR-T allogènes. Les points forts de sa carrière incluent :
- Levée de plus de 500 millions de dollars en financements propres
- Formation de partenariats d'une valeur supérieure à 4 milliards de dollars
- Cofondation de Precision BioSciences (DTIL) en 2006
- Direction de l'IPO de Precision et développement de quatre thérapies CAR-T allogènes
- Rôle récent de PDG chez Tune Therapeutics, une entreprise d'édition épigénétique
La nomination de Kane est en adéquation avec l'accent mis par Celyad sur la technologie CAR-T et ses plans ambitieux de croissance et de développement dans le domaine de l'oncologie.
Celyad Oncology (Euronext: CYAD) hat Matt Kane zu seinem neuen CEO mit Wirkung zum 1. Oktober 2024 ernannt. Kane bringt über 20 Jahre Erfahrung in unternehmerischen, CEO- und Vorstandspositionen mit und verfügt über Fachkenntnisse in Genom-Editing und allogenen CAR-T-Zelltherapien. Zu den Höhepunkten seiner Karriere gehören:
- Beschaffung von über 500 Millionen Dollar in Eigenkapitalfinanzierungen
- Bildung von Partnerschaften im Wert von über 4 Milliarden Dollar
- Mitgründung von Precision BioSciences (DTIL) im Jahr 2006
- Leitung des IPO von Precision und Entwicklung von vier allogenen CAR-T-Therapien
- Jüngste CEO-Position bei Tune Therapeutics, einem Unternehmen für epigenetische Bearbeitung
Kanens Ernennung steht im Einklang mit Celyads Fokus auf CAR-T-Technologie und den ehrgeizigen Wachstums- und Entwicklungsplänen im Onkologiesektor.
- Appointment of a highly experienced CEO with over 20 years in the biotech industry
- New CEO has expertise in allogeneic CAR T-cell therapies, aligning with Celyad's focus
- Matt Kane has a strong track record in raising capital ($500M+) and forming valuable partnerships ($4B+)
- Kane's experience in leading a company through IPO could be beneficial for Celyad's future growth
- None.
MONT-SAINT-GUIBERT,
Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad”) is pleased to announce Matt Kane as its new Chief Executive Officer (CEO), effective as of October 1st, 2024.
Matt Kane is a seasoned executive with over 20 years of experience in entrepreneurial, CEO and board roles. Mr. Kane is a pioneer in genome editing, led the development of the first editing technology to receive clearance for clinical evaluation as an in vivo gene insertion therapeutic and, most importantly, led the development and clinical testing of multiple allogeneic chimeric antigen receptor (CAR) T-cell therapies directed against cancer. His extensive scientific and business acumen have been demonstrated during his career by raising over
Mr. Kane is currently involved with several entrepreneurial initiatives within the biotechnology industry. Until recently, he served as CEO and board member of Tune Therapeutics, Inc., an epigenetic editing biotechnology company. During his tenure at Tune, he led the development of the initial program portfolio, followed by the selection of a lead epi-editing therapeutic candidate. Prior to Tune Therapeutics, Matt co-founded the gene editing company, Precision BioSciences, Inc. (DTIL), in 2006 and led the company as CEO and board member until 2021. While leading Precision, he oversaw the company’s Initial Public Offering, formed several pharmaceutical partnerships across cell and gene therapy, and ultimately directed four unique allogeneic CAR T therapies into human clinical studies.
Mr. Kane holds a Master of Business Administration, Certificate in Health Sector Management, from Duke University, a Master of Biomedical Engineering and a Bachelor of Mechanical Engineering, both from the Rose-Hulman Institute of Technology.
Hilde Windels, Chair of the Board, commented: “We are very pleased to announce that Matt has been appointed as our new CEO. His in-depth expertise in the CAR T space and his pioneering work at Precision BioSciences (amongst others) are ideal to help Celyad execute its ambitious plans. We congratulate Matt and wish him all the best in his new role.”
“I am thrilled to have the opportunity to join Celyad Oncology as its next Chief Executive Officer and, alongside this stellar team, build upon the tremendous progress, deep intellectual property portfolio, and key scientific insights generated by the Company,” commented Matt Kane.
Michel Lussier, co-founder of Celyad Oncology and Interim CEO, added: “Leading Celyad at our current stage of development requires a very unique set of skills: in-depth knowledge of the CAR T space, seasoned expertise in R&D out-licensing and IP monetization. We are very fortunate that Matt brings a solid track record in all these aspects.“
About Celyad Oncology
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert,
Celyad Oncology Forward-Looking Statement
This release may contain forward-looking statements, including, without limitation, statements regarding beliefs about and expectations for the Company’s updated strategic business model, including associated potential benefits, transactions and partnerships, statements regarding the Company’s hiring plans, and statements regarding the Company’s hiring of a new CEO. The words “will,” “potential,” “continue,” “target,” “project,” “should” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this release are based on management’s current expectations and beliefs and are subject to a number of known and unknown risks, uncertainties and important factors which might cause actual events, results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks related to the material uncertainty about the Company’s ability to continue as a going concern; the Company’s ability to realize the expected benefits of its updated strategic business model; the Company’s ability to develop its IP assets and enter into partnerships with outside parties; the Company’s ability to enforce its patents and other IP rights; the possibility that the Company may infringe on the patents or IP rights of others and be required to defend against patent or other IP rights suits; the possibility that the Company may not successfully defend itself against claims of patent infringement or other IP rights suits, which could result in substantial claims for damages against the Company; the possibility that the Company may become involved in lawsuits to protect or enforce its patents, which could be expensive, time-consuming, and unsuccessful; the Company’s ability to protect its IP rights throughout the world; the potential for patents held by the Company to be found invalid or unenforceable; and other risks identified in the latest Annual Report and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
Source: Celyad Oncology SA
View source version on businesswire.com: https://www.businesswire.com/news/home/20240916004235/en/
Investor and Media Contact:
David Georges
VP of Finance and Administration
Celyad Oncology
investors@celyad.com
Source: Celyad Oncology SA
FAQ
When will Matt Kane start as CEO of Celyad Oncology (CYAD)?
What is Matt Kane's background in relation to Celyad Oncology's (CYAD) focus?
What are some of Matt Kane's notable achievements before joining Celyad Oncology (CYAD)?